Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
10:46am, Thursday, 04'th Jul 2024
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
01:46pm, Wednesday, 03'rd Jul 2024
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology co
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
10:18am, Wednesday, 03'rd Jul 2024
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
07:59am, Wednesday, 03'rd Jul 2024
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
07:53am, Wednesday, 03'rd Jul 2024
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vacc
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
05:21am, Wednesday, 03'rd Jul 2024
For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for co
GSK takes full control of flu vaccine programme in €1.45bn deal
03:11am, Wednesday, 03'rd Jul 2024
GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Ge
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
02:40am, Wednesday, 03'rd Jul 2024
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to
GSK buys full rights to make COVID, influenza vaccines from CureVac
02:26am, Wednesday, 03'rd Jul 2024
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euro
CDC Narrows Age Recommendation for Use of RSV Vaccine
12:20pm, Friday, 28'th Jun 2024
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
01:14pm, Thursday, 27'th Jun 2024
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
Biotech Stock Slips on CDC Buzz
10:48am, Thursday, 27'th Jun 2024
British biotech stock GSK plc (NYSE:GSK) is trading lower, though it pared its steeper losses today, down 1% at $38.49 at last glance after earlier sliding as much as 7%.
Here's Why GSK (GSK) is a Strong Value Stock
10:40am, Thursday, 27'th Jun 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK and Moderna slide on RSV vaccine CDC updates
04:00am, Thursday, 27'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, f
GSK stock falls more at London open following RSV vaccination news
03:58am, Thursday, 27'th Jun 2024
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated aga
